Q4 2019 Amarin Corporation PLC Earnings Call Transcript
Welcome to Amarin Corporation's conference call to discuss its financial and operating results for the fourth quarter and full year of 2019. This conference call is being recorded today, February 25, 2020.
I would now like to turn the conference call over to Elisabeth Schwartz, Senior Director of Investor Relations of Amarin.
Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding our commercial and financial performance, including levels of Vascepa prescriptions; Vascepa product and licensing revenues, costs and other commercial metrics, gross margin, expenditures, such as for the purchase of additional supply of Vascepa, and the adequacy of our financial resources; our current expectations for additional scientific presentations, publications, medical guidelines and regulatory reviews outside the United
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |